Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Pharma global manufacturing: improving environment in the UK

Rebecca Aris provides an update on global pharmaceutical manufacturing in the UK following the recent announcement by Eisai to transfer global manufacturing of its new epilepsy medicine to the UK. It came as a huge shock when, in 2011, Pfizer announced that it was to close its UK research site at Sandwich in Kent. The move...

Articles

Patient-centric care and data: the big picture

Pharma companies are continually adjusting their business models – Jasveen Chugh discusses how the patient-centric approach will only work if pharma understands exactly who their customer is. New healthcare models are emerging in response to pressures to contain costs while safeguarding quality. Typically, they feature...

Articles

World Biosimilars Congress 2012: is it up to the goats to sa...

pharmaphorum’s Assistant Editor, Hannah Blake, recently attended the World Biosimilars Congress 2012 – here she comments on the current market trends and what the future holds for biosimilars, biologics and biobetters. It can be said that our healthcare system is stuck in a catch 22. Why? Because our population is ageing, there is a financial...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access